Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | FPR2 | P25090 | 7/20 | 0.50 |
| ▸ | FPR1 | P21462 | 1/20 | 0.47 |
| ▸ | F13A1 | P00488 | 1/20 | 0.46 |
| ▸ | TGM2 | P21980 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL889076 | 0.90 | HTT (0.54) | KMT2ANPC1RAB9AMEN1MAPT | |
| SCHEMBL889034 | 0.90 | SMN1; SMN2 (0.50) | KMT2ANPC1RAB9AMEN1MAPT | |
| SCHEMBL889041 | 0.90 | KMT2A (0.66) | KMT2ANPC1RAB9AMEN1MAPT | |
| SCHEMBL19297616 | 0.79 | F13A1 (0.49) | KMT2ANPC1RAB9AMEN1MAPT | |
| SCHEMBL2628758 | 0.77 | TRPM8 (0.73) | KMT2ANPC1RAB9AMEN1MAPT | |
| SCHEMBL2719839 | 0.77 | NAMPT (0.67) | KMT2ANPC1RAB9AMEN1MAPT | |
| SCHEMBL7824367 | 0.75 | RAB9A (0.72) | KMT2ARAB9AMEN1MAPTSMN1; SMN2 | |
| SCHEMBL12810176 | 0.75 | FPR2 (0.48) | FPR2 | |
| SCHEMBL13696943 | 0.74 | NPC1 (0.68) | KMT2ANPC1RAB9AMEN1MAPT | |
| SCHEMBL6556747 | 0.73 | CHRNA7 (0.62) | NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822700-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8815928-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8759332-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8703938-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20110070197-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| US-20110064695-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110064696-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110064697-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110064697-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | KMT2A 2992/4885NPC1 34/4885RAB9A 3060/4885 |
| US-20110064695-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | KMT2A 2992/4885NPC1 34/4885RAB9A 3060/4885 |
| US-20110064696-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | KMT2A 2992/4885NPC1 34/4885RAB9A 3060/4885 |
| US-20110070197-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | KMT2A 2992/4885NPC1 34/4885RAB9A 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.